Macquarie Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-163,578
Closed -$2.94M 2393
2020
Q2
$2.94M Sell
163,578
-335,888
-67% -$4.67M 0.01% 909
2020
Q1
$3.56M Sell
499,466
-70,968
-12% -$886K 0.01% 791
2019
Q4
$13.6M Buy
570,434
+21,752
+4% +$600K 0.02% 594
2019
Q3
$14.7M Buy
548,682
+43,469
+9% +$1.22M 0.02% 520
2019
Q2
$13.7M Sell
505,213
-43,066
-8% -$1.35M 0.02% 544
2019
Q1
$19M Sell
548,279
-37,299
-6% -$1.08M 0.03% 474
2018
Q4
$11.4M Buy
585,578
+205,220
+54% +$4.22M 0.02% 573
2018
Q3
$10.1M Buy
380,358
+207,358
+120% +$6.77M 0.02% 642
2018
Q2
$6.53M Buy
+173,000
New +$6.62M 0.01% 721
2017
Q1
Sell
-39,201
Closed -$880K 1584
2016
Q4
$880K Hold
39,201
﹤0.01% 1190
2016
Q3
$890K Sell
39,201
-32,099
-45% -$753K ﹤0.01% 1176
2016
Q2
$1.68M Buy
71,300
+45,100
+172% +$1.11M ﹤0.01% 1185
2016
Q1
$534K Sell
26,200
-18,621
-42% -$591K ﹤0.01% 1224
2015
Q4
$2.31M Buy
44,821
+581
+1% +$28.2K ﹤0.01% 901
2015
Q3
$1.89M Sell
44,240
-23,572
-35% -$1.14M ﹤0.01% 986
2015
Q2
$3.09M Buy
67,812
+36
+0.1% +$1.45K 0.01% 902
2015
Q1
$2.57M Buy
67,776
+3,292
+5% +$113K 0.01% 949
2014
Q4
$1.83M Buy
64,484
+4,301
+7% +$120K ﹤0.01% 1041
2014
Q3
$1.52M Buy
60,183
+353
+0.6% +$9.3K ﹤0.01% 1081
2014
Q2
$1.75M Buy
59,830
+1,412
+2% +$34.2K ﹤0.01% 1084
2014
Q1
$1.51M Buy
58,418
+4,735
+9% +$126K ﹤0.01% 1086
2013
Q4
$1.38M Buy
+53,683
New +$1.3M ﹤0.01% 1091

Macquarie Group's PTLA Position: Q3 2020 in Review

Macquarie Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 163,578 shares — an estimated $2.94M sold.

Macquarie Group first reported a position in PTLA in Q4 2013 and held it in 22 quarters. The position peaked at $19M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Macquarie Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Macquarie Group sold 163,578 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2.94M.
  • Macquarie Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 22 quarters.
  • Macquarie Group's Portola Pharmaceuticals, Inc. position peaked at $19M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Macquarie Group's 13F filing for Q3 2020, filed 13 Nov 2020.